Lilly Eyes AtaiBeckley Buyout as Foundayo Forecast Slashed
LLY sits 86% above its 52-week low of $623.78.
Summary
Eli Lilly is in advanced talks to acquire AtaiBeckley for $9–$11 per share, a deal that would expand its neuroscience pipeline. Separately, Deutsche Bank cut its 2026 sales forecast for obesity drug Foundayo to $1.3B from ~$3B, citing slower prescription uptake, though Lilly expects growth as familiarity increases. Citi raised its price target to $1,600, reflecting continued confidence. The mixed signals—a potential acquisition and a major forecast cut—create uncertainty around near-term growth drivers.
At the time of this announcement, LLY was trading at $1,157.27 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.